×
Pieris Pharmaceuticals SG&A Expenses 2014-2024 | PVLA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Pieris Pharmaceuticals sg&a expenses from 2014 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
View More
Pieris Pharmaceuticals SG&A Expenses 2014-2024 | PVLA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Pieris Pharmaceuticals sg&a expenses from 2014 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Related Stocks
Company Name
Market
Cap
NPK (NPKI)
$626M
Performant Healthcare (PHLT)
$245M
FTAC Emerald Acquisition (FLDD)
$158M
Swiftmerge Acquisition (ANNA)
$42M
Insight Acquisition (AMOD)
$23M
Hanryu Holdings (GITS)
$17M
LQR House (YHC)
$11M
ATIF Holdings (ZBAI)
$9M
Lion Electric (LEVGQ)
$0M